Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
20.52
-2.98 (-12.68%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ultragenyx Pharmaceutical Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
July 14, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
July 11, 2025
Via
Benzinga
Market Monitor News July 11 BMO (Airline stocks UP - Ultragenyx Pharmaceuticals DOWN)
↗
July 11, 2025
Investors shrug off tariff drama as earnings, chip euphoria, and airline optimism steal the show.
Via
Chartmill
Topics
World Trade
Breaking Down Ultragenyx Pharmaceutical: 4 Analysts Share Their Views
↗
July 10, 2025
Via
Benzinga
What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
↗
May 28, 2025
Via
Benzinga
Earnings Scheduled For May 6, 2025
↗
May 06, 2025
Via
Benzinga
Ultragenyx Pharmaceutical's Earnings: A Preview
↗
May 05, 2025
Via
Benzinga
Breaking Down Ultragenyx Pharmaceutical: 7 Analysts Share Their Views
↗
February 14, 2025
Via
Benzinga
Let's take a look at the stocks that are in motion in today's session.
↗
July 10, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
July 10, 2025
Via
Benzinga
Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings
↗
July 10, 2025
Via
Benzinga
Which stocks are experiencing notable movement on Thursday?
↗
July 10, 2025
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
Earnings Scheduled For February 13, 2025
↗
February 13, 2025
Via
Benzinga
Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views
↗
January 22, 2025
Via
Benzinga
US Stocks Mixed; Initial Jobless Claims Fall
↗
July 10, 2025
Via
Benzinga
Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease
↗
July 10, 2025
The study will continue onto a third and final analysis toward the end of the year.
Via
Investor's Business Daily
Thursday's session: gap up and gap down stocks
↗
July 10, 2025
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.
Via
Chartmill
Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win
↗
July 10, 2025
Ultragenyx shares fall after Phase 3 study misses interim target, but analysts remain positive ahead of final OI data expected later this year.
Via
Benzinga
Get insights into the top gainers and losers of Thursday's pre-market session.
↗
July 10, 2025
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
July 10, 2025
Via
Benzinga
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
July 10, 2025
Via
Benzinga
Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket
↗
July 10, 2025
Via
Benzinga
Ultragenyx, Mereo Sink After Hours As Bone Drug Trial Continues Without Early Stop; Retail Traders Feel Selloff Is Overdone
↗
July 10, 2025
The companies now expect final data from the Orbit and Cosmic studies by the end of the year.
Via
Stocktwits
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
July 09, 2025
Via
Benzinga
What's going on in today's after hours session
↗
July 09, 2025
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
Ultragenyx Pharmaceutical Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
↗
June 20, 2025
Via
Benzinga
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028
↗
May 28, 2025
Ultragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for 2027.
Via
Benzinga
8 Health Care Stocks Whale Activity In Today's Session
↗
May 01, 2025
Via
Benzinga
Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning
↗
March 27, 2025
JP Morgan sees strong upside for Ultragenyx, citing setrusumab trial progress and pipeline growth, raising the price target to $117.
Via
Benzinga
Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews
↗
March 17, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today